Filing Details
- Accession Number:
- 0001209191-22-052221
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-10-04 16:22:41
- Reporting Period:
- 2022-10-03
- Accepted Time:
- 2022-10-04 16:22:41
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1812364 | Relay Therapeutics Inc. | RLAY | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1709772 | A Donald Bergstrom | C/O Relay Therapeutics, Inc. 399 Binney Street, 2Nd Floor Cambridge MA 02139 | President, R&D | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-10-03 | 8,000 | $4.12 | 96,683 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-10-03 | 8,000 | $22.43 | 88,683 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2022-10-03 | 8,000 | $0.00 | 8,000 | $4.12 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 101,456 | 2028-04-09 | No | 4 | M | Direct |
Footnotes
- The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 7, 2022.
- Includes 78,707 shares underlying restricted stock units.
- This transaction was executed in multiple trades at prices ranging from $22.09 to $22.98. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- Twenty-five percent (25%) of the shares underlying this option vested on April 2, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.
Billionaire Hedge Funds
